- Home
- WES vs MEDP Comparison
WES vs MEDP Comparison
Compare WES & MEDP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | WES | MEDP |
|---|---|---|
| Founded | 2007 | 1992 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Natural Gas Distribution | Biotechnology: Commercial Physical & Biological Resarch |
| Sector | Utilities | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 17.3B | 15.4B |
| IPO Year | 2012 | 2016 |
Fundamental Metrics
Financial Performance| Metric | WES | MEDP |
|---|---|---|
| Price | $46.96 | $585.01 |
| Analyst Decision | Hold | Hold |
| Analyst Count | 7 | 12 |
| Target Price | $41.71 | ★ $473.17 |
| AVG Volume (30 Days) | ★ 745.7K | 370.2K |
| Earning Date | 05-06-2026 | 04-22-2026 |
| Dividend Yield | ★ 8.81% | N/A |
| EPS Growth | N/A | ★ 20.98 |
| EPS | N/A | ★ 8.53 |
| Revenue | ★ $3,843,403,000.00 | N/A |
| Revenue This Year | $6.42 | $13.19 |
| Revenue Next Year | $6.99 | $7.75 |
| P/E Ratio | ★ $14.73 | $68.90 |
| Revenue Growth | ★ 6.61 | N/A |
| 52 Week Low | $36.90 | $373.00 |
| 52 Week High | $48.63 | $677.90 |
Technical Indicators
Market Signals| Indicator | WES | MEDP |
|---|---|---|
| Relative Strength Index (RSI) | 57.40 | 63.66 |
| Support Level | $39.67 | $568.34 |
| Resistance Level | $48.32 | $621.43 |
| Average True Range (ATR) | 0.94 | 21.73 |
| MACD | -0.12 | -0.91 |
| Stochastic Oscillator | 49.01 | 44.99 |
Price Performance
Historical ComparisonAbout WES Western Midstream Partners LP
Western Midstream Partners LP is a USA-based company which own, operate, acquire and develop midstream energy assets. The company through its subsidiary is engaged in the business of gathering, processing, compressing, treating and transporting natural gas, condensate, NGLs and crude oil. It owns or has investments in assets located in the Rocky Mountains (Colorado, Utah, and Wyoming), the Mid-Continent (Kansas and Oklahoma) and Texas.
About MEDP Medpace Holdings Inc.
Medpace is a late-stage contract research organization that provides full-service drug-development and clinical trial services to small and midsize biotechnology, pharmaceutical, and medical device firms. It also offers ancillary services, including bioanalytical laboratory services and imaging capabilities. The company was founded over 30 years ago and has more than 5,400 employees across 40 countries. Medpace is headquartered in Cincinnati, Ohio, and its operations are primarily based in the US, with additional presence in Europe, Asia, South America, Africa, and Australia. Cinven, a global private equity firm, acquired Medpace for $915 million in 2014 and exited its investment in 2018.